Navigation Links
Novartis Drug SOM230 is First Medical Therapy to Show Efficacy in a Phase III Trial in Cushing's Disease, a Debilitating Hormonal Disorder
Date:9/21/2010

EAST HANOVER, N.J., Sept. 22 /PRNewswire-FirstCall/ -- Novartis Pharmaceuticals Corporation ("Novartis") (NYSE: NVS) announced today that the results of a Phase III study of SOM230 (pasireotide) showed a reduction in cortisol levels in patients with Cushing's disease, a condition in which a benign (non-cancerous) pituitary tumor causes the adrenal glands to produce excess cortisol and can be fatal(1). Results will be presented at the 14th Congress of the European Neuroendocrine Association (ENEA).

At six months, the majority of evaluable patients (91/103) experienced a reduction from baseline in urinary free cortisol (UFC) levels, the main measure of biochemical control of the disease. UFC levels were normalized in 26% of patients randomized to SOM230 900ug twice daily, meeting the primary endpoint of the study. Additionally, median UFC was reduced by 48% in both the 900ug and 600ug dose groups. After 12 months of treatment, results confirmed the durability of the effect(1).

On average, as UFC levels were reduced, clinical symptoms of Cushing's disease improved including reduction of blood pressure, total cholesterol, weight and body mass index (BMI)(1).

Cushing's disease is caused by a benign tumor in the pituitary gland that secretes adrenocorticotropic hormone (ACTH), which triggers the adrenal glands to produce excess cortisol. Cortisol is a powerful steroid hormone that regulates a broad range of physiologic functions, including metabolism and immunity(2). Cushing's disease can cause severe cardiovascular and metabolic-related illnesses or death(3),(4). There are currently no approved medicines to treat Cushing's disease(1).

"There is a critical need for a medical treatment for people with Cushing's disease because currently available options, such as surgery or radiotherapy, are ultimately not effective for many of the patients who suffer from this d
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 InVivo Therapeutics Holdings ... is revolutionizing spinal cord injury (SCI) treatment ... shown to outperform in tissue regrowth in the spinal ... Made from an FDA approved polymer, the scaffold ultimately ... harmless to the human body. NVIV has recently attracted ...
(Date:10/22/2014)... YORK , Oct. 22, 2014 Provectus ... dermatology therapies. PV-10, its novel investigational drug for cancer, ... potential for systemic side effects. Its oncology focus is ... Provectus has completed phase 2 trials of PV-10 as ... a topical treatment for atopic dermatitis and psoriasis. ...
(Date:10/22/2014)... SHANGHAI , Oct. 22, 2014   ... and WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... comprehensive genomic profiling to biopharmaceutical companies conducting clinical trials ... Under the terms of the collaboration, Foundation Medicine will ... of Foundation Medicine,s FoundationOne® assay at the WuXi Genome ...
Breaking Medicine Technology:InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5
... LA JOLLA, Calif. , April 28 ... industry speakers and open registration for its Wireless Health Commercialization ... part of the 5th annual WLSA Convergence Summit, a three-day ... creating value and improving health through wireless communications technologies. The ...
... The biopharma mega-mergers that grabbed headlines last year - Roche + Genentech, ... critical post-integration period and the acquiring companies are finding out how well ... verdicts, but clearly one M&A issue that continues to create problems for ... , , ...
Cached Medicine Technology:Thought Leaders Shaping the Emerging Wireless Life Science Space to Share Vision and Insights at WLSA Convergence Summit 2Thought Leaders Shaping the Emerging Wireless Life Science Space to Share Vision and Insights at WLSA Convergence Summit 3Thought Leaders Shaping the Emerging Wireless Life Science Space to Share Vision and Insights at WLSA Convergence Summit 4Bio-Pharma Industry Experts Deliver M&A Value Through Integration Excellence 2Bio-Pharma Industry Experts Deliver M&A Value Through Integration Excellence 3
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. ... three Ebola cases in Dallas. But, mental health specialists say ... President Barack Obama on Friday appointed an Ebola "czar" ... infected two Dallas nurses who cared for a Liberian man ... Hospital. But the U.S. cases are miniscule in the ...
(Date:10/22/2014)... With the Affordable Care Act (ACA) open enrollment period ... for Research (AIR) finds that three out of four Americans ... 42 percent say they are not likely or only somewhat ... coverage. , The AIR survey found wide gaps in Americans’ ... correctly how much they owe for a routine doctor’s visit. ...
(Date:10/22/2014)... Although there are only 24 hours in a ... who have trouble finding time within their busy schedules for exercise ... periods of time to get in shape. Here are five ways ... go. , Change Up Your Commute , Consider riding a ... some exercise into your daily routine. If you must use your ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... undergoing in vitro fertilization (IVF) are only about half as ... assisted reproduction technique, new research indicates, and the racial disparity ... study, about 31 percent of white patients became pregnant after ... Analyzing more than 4,000 IVF cycles over two years to ...
(Date:10/22/2014)... HealthDay Reporter , MONDAY, Oct. 20, 2014 (HealthDay ... for health workers treating Ebola patients, now requiring full body ... at all times. The U.S. Centers for Disease Control ... Dallas nurses contracted Ebola while caring for the first ... Duncan. Nina Pham is currently being treated for her infection ...
Breaking Medicine News(10 mins):Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 2Health News:Ebola Anxiety: A Bigger Threat Now Than the Virus Itself 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3
... Sept. 13 Arrow International,Inc. (Nasdaq: ARRO ) ... today on the WHITE proxy card for its planned ... to re-elect the Arrow Board of,Directors, who are committed ... of Arrow common stock to shareholders once the,merger is ...
... VILLAGE, Calif., Sept. 13 Hackensack,University Medical ... located,in Hackensack, N.J., and affiliated with The ... Jersey Medical School, is the first hospital ... experience in all,four service areas: inpatient, outpatient, ...
... The Century Foundation with support from The Commonwealth,Fund, and AARP, NEW YORK, Sept. 13 ... Blogging Live from "Business and National Health Care ... TCF Fellow Maggie Mahar, author of Money-Driven Medicine: ... So Much (Harper/Collins ...
... founder of,Manifestingtruth.com, has been amazing people from all over ... Course." This,powerful course was channeled through Anna by her ... hope for people from all walks of,life. "I ... met ... as I listened to you,and started taking ...
... treatments for sensory disorders in which people experience the ... MIT researchers report that they have identified the gene ... whose eyes on the sides of their heads provide ... Now researchers from the Picower Institute for Learning and ...
... 13 The following was,released today by the U.S. Department of Health and Human Services:, WHO: ... Jay E. Berkelhamer, M.D., F.A.A.P., President, ... Daniel Schneider, J.D., Acting ... for Children and Families ...
Cached Medicine News:Health News:Arrow International Sends Letter Reminding Shareholders to Vote White Proxy Card in Support of Teleflex Merger and Election of Current Board of Directors 2Health News:Arrow International Sends Letter Reminding Shareholders to Vote White Proxy Card in Support of Teleflex Merger and Election of Current Board of Directors 3Health News:Arrow International Sends Letter Reminding Shareholders to Vote White Proxy Card in Support of Teleflex Merger and Election of Current Board of Directors 4Health News:J.D. Power and Associates Reports: Hackensack University Medical Center Recognized as First Hospital to Achieve Distinction for Providing an Outstanding Inpatient Experience in All Four Service Areas 2Health News:J.D. Power and Associates Reports: Hackensack University Medical Center Recognized as First Hospital to Achieve Distinction for Providing an Outstanding Inpatient Experience in All Four Service Areas 3Health News:TCF Fellow Maggie Mahar to Blog Live from Business and National Health Care Reform Conference 2Health News:TCF Fellow Maggie Mahar to Blog Live from Business and National Health Care Reform Conference 3Health News:Spiritual Healer/Psychic-Medium Reaches International Status! 2Health News:MIT IDs binocular vision gene 2Health News:Acting Surgeon General Announces National Initiatives to Protect Children by Reducing Exposure to Secondhand Smoke 2
Non-dissolvable Herrick Lacrimal Plugs provide long-term lacrimal occlusion through partial blockage of the horizontal canaliculus....
10 (mm) smooth platform; Serrated handle in stainless steel....
... first digital solution designed specifically for cardiologists ... outside cardiology. From the server core to ... combined expertise in both cine film and ... work the way they want, wherever they ...
... Medison SonoAce 9900 is ... based ultrasound system, with ... is DICOM compatible, designed ... general imaging, obstetrics, gynecology, ...
Medicine Products: